These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 11025617)

  • 21. [Inhibitors (antibodies) directed against factor VIII in hemophilia A (author's transl)].
    Beck EA
    Ther Umsch; 1979 Apr; 36(4):326-9. PubMed ID: 377556
    [No Abstract]   [Full Text] [Related]  

  • 22. Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses.
    Ettinger RA; James EA; Kwok WW; Thompson AR; Pratt KP
    Blood; 2009 Aug; 114(7):1423-8. PubMed ID: 19549986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune tolerance in two high responder, severe hemophilia A patients with inhibitors: the importance of high doses and the duration of the treatment.
    Ciavarella N; Schiavoni M; Fasano A; Giliberti MG; Ettorre C; Stefanile C
    Vox Sang; 1996; 70 Suppl 1():72-3. PubMed ID: 8869475
    [No Abstract]   [Full Text] [Related]  

  • 24. Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody.
    Monahan PE; Aledort LM;
    Am J Hematol; 2004 Dec; 77(4):346-50. PubMed ID: 15558804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects.
    Reding MT; Wu H; Krampf M; Okita DK; Diethelm-Okita BM; Christie BA; Key NS; Conti-Fine BM
    Thromb Haemost; 2000 Oct; 84(4):643-52. PubMed ID: 11057864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A.
    van Helden PM; van den Berg HM; Gouw SC; Kaijen PH; Zuurveld MG; Mauser-Bunschoten EP; Aalberse RC; Vidarsson G; Voorberg J
    Br J Haematol; 2008 Aug; 142(4):644-52. PubMed ID: 18510679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. von Willebrand factor and transforming growth factor-beta modulate immune response against coagulation factor VIII in FVIII-deficient mice.
    Kallas A; Kuuse S; Maimets T; Pooga M
    Thromb Res; 2007; 120(6):911-9. PubMed ID: 17376515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia.
    Wootla B; Mahendra A; Dimitrov JD; Friboulet A; Borel-Derlon A; Rao DN; Uda T; Borg JY; Bayry J; Kaveri SV; Lacroix-Desmazes S
    FEBS Lett; 2009 Aug; 583(15):2565-72. PubMed ID: 19595998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
    Delignat S; Dasgupta S; André S; Navarrete AM; Kaveri SV; Bayry J; André MH; Chtourou S; Tellier Z; Lacroix-Desmazes S
    Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haemophilic patients with inhibitors to factor VIII or IX: variables affecting treatment response.
    Penner JA
    Haemophilia; 2001 Jan; 7(1):103-8. PubMed ID: 11136390
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunological aspects of inhibitor development.
    Reding MT
    Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Von Willebrand factor-specific antibodies developing upon treatment of FVIII-deficient mice with different FVIII preparations.
    Kallas A; Kuuse S; Maimets T; Pooga M
    Acta Haematol; 2008; 119(4):244-7. PubMed ID: 18594135
    [No Abstract]   [Full Text] [Related]  

  • 33. Spontaneous disappearance of high titre factor VIII inhibitor 15 years after unsuccessful ITI.
    Thom K; Male C; Falger J; Pabinger I
    Hamostaseologie; 2009 May; 29(2):149-50. PubMed ID: 19404512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors.
    Orsini F; Rotschild C; Beurrier P; Faradji A; Goudemand J; Polack B
    Haematologica; 2005 Sep; 90(9):1288-90. PubMed ID: 16154861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune response against therapeutic factor VIII in hemophilia A patients--a survey of probable risk factors.
    Dasgupta S; Navarrete AM; Delignat S; Wootla B; Andre S; Nagaraja V; Lacroix-Desmazes S; Kaveri SV
    Immunol Lett; 2007 May; 110(1):23-8. PubMed ID: 17467813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A.
    Reipert BM; Ahmad RU; Turecek PL; Schwarz HP
    Thromb Haemost; 2000 Nov; 84(5):826-32. PubMed ID: 11127864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells.
    Kaveri SV; Dasgupta S; Andre S; Navarrete AM; Repessé Y; Wootla B; Lacroix-Desmazes S
    Haemophilia; 2007 Dec; 13 Suppl 5():61-4. PubMed ID: 18078399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-factor VIII antibodies: a 2005 update.
    Lavigne-Lissalde G; Schved JF; Granier C; Villard S
    Thromb Haemost; 2005 Oct; 94(4):760-9. PubMed ID: 16270627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of VWF in the immunogenicity of FVIII.
    Lacroix-Desmazes S; Repessé Y; Kaveri SV; Dasgupta S
    Thromb Res; 2008; 122 Suppl 2():S3-6. PubMed ID: 18549909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does peroral administration of factor VIII induce oral tolerance in patients with acquired haemophilia A?
    Lindgren A; Wadenvik H; Tarkowski A; Tengborn L
    Thromb Haemost; 2000 Apr; 83(4):632-3. PubMed ID: 10780332
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.